Equity
-€8,431
Debts exceed assets in financial year 2025.
NANO PHARMA
Lifetime
8 annual accounts with figures on one time axispeak €33,506 (2018)
-€9,458▲ €30,823
lowest -€41,194 (2024)
-€11,159▲ €30,035
peak €68,106 (2020)
-€8,431▼ €11,159
€24,734▲ 19.8%
Board1 name since 2016
1 directorKAMOUN Farah
Documentsfilings and deeds
14-01-202617 days before the deadline
2025micro format
Gross margin from -€40,281 to -€9,458Loss of €11,159Equity from €2,728 to -€8,431Debts from €20,650 to €24,734
Key points
from the 2025 annual accountsLosses
-€52,353 in two years
The 2024 and 2025 financial years closed with a loss. 2024 was the heaviest.
Debts
€24,734 152% of the balance sheet
Liquidity
0.64 was 1.09 in 2024
Short-term debts rose from €20,650 to €24,734.
Filings
8 annual accounts 2 late
The 2018 accounts came latest: 26 days after the end of the period.
Position in the sector
-51.7%
Lower solvency than 87% of companies in retail trade. Sector median 33.1% · 22,924 companies.
Turnover not published (micro format)
Checked score
53
Fair
Financially stronger than 17% of micro companies in retail trade (NACE 47)
Probability in this band: 1.5% to 4.2%
Negative equity caps the score at 59.
Bankruptcy probability within 12 months
0.9% Low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: 0.6% across 40,275 companies (NACE 47, micro).
About 9 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: 0.3%lowest value
01-2025: 1.6%▲ +1.3 percentage points vs 12-2024
02-2025: 1.6%● unchanged vs 01-2025
03-2025: 1.4%▼ -0.2 percentage points vs 02-2025
04-2025: 1.4%● unchanged vs 03-2025
05-2025: 1.4%● unchanged vs 04-2025
06-2025: 1.4%● unchanged vs 05-2025
07-2025: 1.4%● unchanged vs 06-2025
08-2025: 1.4%● unchanged vs 07-2025
09-2025: 1.4%● unchanged vs 08-2025
10-2025: 1.5%▲ +0.1 percentage points vs 09-2025
11-2025: 1.6%▲ +0.1 percentage points vs 10-2025
12-2025: 1.6%● unchanged vs 11-2025
01-2026: 1.7%▲ +0.1 percentage points vs 12-2025highest value
02-2026: 1.0%▼ -0.7 percentage points vs 01-2026
03-2026: 1.0%● unchanged vs 02-2026
04-2026: 1.0%● unchanged vs 03-2026
05-2026: 1.0%● unchanged vs 04-2026
06-2026: 1.0%● unchanged vs 05-2026
07-2026: 1.0%● unchanged vs 06-2026
08-2026: 1.0%● unchanged vs 07-2026
09-2026: 1.0%● unchanged vs 08-2026
10-2026: 0.9%▼ -0.1 percentage points vs 09-2026
11-2026: 0.9%● unchanged vs 10-2026
Financial strengthWeak
Score breakdown
raises risk
Capped at 59: negative equity
Negative equity -€8,431
Loss of €11,159, the second in a row (financial year 2025)
lowers risk
Size: total assets €16,303
Liquidity: current ratio 0.64, cash €11,446
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 47, micro). It does better than 6% of them on solvency, 52% on liquidity, 6% on profitability and 2% on growth.
The bankruptcy probability was computed on 09-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 30-06-2025.
Of the companies with a bankruptcy probability in the low class on 30-06-2025, 0.8% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 6,907 companies had the same profile as NANO PHARMA has now. Each dot stands for 18 companies, two years later.
85.4%
were still trading
8.1%
stopped another way
5.8%
went bankrupt
Another 0.7% stopped without a precise date, possibly only after those two years.
The bankruptcy probability of NANO PHARMA itself is lower: 0.9% within 12 months. It rests on far more data about NANO PHARMA than the profile alone.
Test of the method
The method was tested on the 497,447 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 6,907 companies, not a prediction for NANO PHARMA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
No credit on open account
Liquidity is insufficient, with a current ratio of 0.64 (1.09 in 2024), below 1. Short-term debt is 151.7% and cash 70.2% of total assets. Equity is negative.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Six signals.
lowers riskraises riskneutral
raises risk · Negative equity
The 2025 annual accounts show negative equity and a net loss.
NBB · annual accounts 2025Equity per financial year
19202122232425
2019 to 2025 · latest year -€8,431
neutral · Latest accounts filed on time
The financial year that closed on 30-06-2025 was due by 31-01-2026 and was filed on 14-01-2026, 17 days ahead of the deadline.
NBB · 8 filingsDeviation from the deadline
2025
17 days early
2024
45 days early
2023
50 days early
2022
54 days early
2021
53 days early
2020
3 days early
2019
26 days late
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 28 days before the deadline. In the sector (NACE 47), the median for financial year 2024 was on the deadline day, and 47% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The financial year that closed on 30-06-2026 is due by 31-01-2027. Nothing is late today. The company usually files around 12 December (4 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
30-06-2026 year end10-11-2026 today31-01-2027 deadline
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0664843344
Registered office moved from Etterbeek to Brussels
New registered office: Avenue de la paix 2/7 à 1081 Bruxelles (Koekelbeerg) · Previous registered office: RUE DES ADUATIQUES 78-1040 ETTERBEEK · General meeting of 29-11-2023 · Gazette deed
Capital contribution of €6,000
KAMOUN Farah holds all the shares · General meeting of 12-12-2022 · Gazette deed
Registered office moved from Uccle to Brussels
New registered office: Rue des aduatiques, 78 à 1180 Bruxelles (Uccle) · Previous registered office: CHAUSSEE DE WATERLOO 873, 1180 UCCLE · General meeting of 09-05-2022 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| NANO PHARMA Koekelberg | - | - | -51.7% | - |
| PharmaSave Antwerp | €7,800 | 9.9% | 54.7% | - |
| LC Pharma Concept Chapelle-lez-Herlaimont | - | - | 32.6% | - |
| ESPACE MEDICAL JUMET Charleroi | - | - | -109.2% | - |
| ABOCOR Liège | - | - | 16.5% | - |
| PMI CONSTRUCTION Arlon | €26,075 | -10.4% | 63.1% | - |
| AJAGA Knokke-Heist | - | - | 42.6% | - |
These companies have the same main activity as NANO PHARMA: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €10,400 and €29,600, founded between 2003 and 2021.
Official details
Source: KBO- Status
- Active since 20-10-2016Normal situation
- Activity
- Retail sale of pharmaceutical productsNACE 47730and 2 others
- Establishment unit
- 2.264.027.7081040 Etterbeek, since 01-01-2017
- Financial year end
- 30 June
- Peppol
- Reachable since 15-12-2025
Annual accounts to 30-06-2025
- €16,303▼ 30.3%
- Filing
- Filed on 14-01-2026, 17 days before the end of the filing period
Insights on NANO PHARMA
NANO PHARMA files the micro format. That format states no turnover. The gross margin fell from €33,506 in 2018 to -€9,458 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about NANO PHARMA
- What is the company number of NANO PHARMA?
- The company number of NANO PHARMA is 0664.843.344. The VAT number is the same number with BE in front: BE 0664.843.344.
- Where is NANO PHARMA based?
- The registered office is at Vredelaan 2, 1081 Koekelberg.Company details
- What does NANO PHARMA do?
- According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
- What is the legal form of NANO PHARMA?
- NANO PHARMA is a private limited company (BV).
- When was NANO PHARMA founded?
- NANO PHARMA was founded on 20-10-2016.
- Is NANO PHARMA still active?
- Yes, NANO PHARMA is an active enterprise in the KBO register.
- What is the turnover of NANO PHARMA?
- The annual accounts for financial year 2025 state no turnover. The micro format does not require it.Financials
- Is NANO PHARMA profitable?
- In financial year 2025, NANO PHARMA made a loss of €11,159.
- Where can I find the annual accounts of NANO PHARMA?
- NANO PHARMA filed 8 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of NANO PHARMA due?
- NANO PHARMA must file the annual accounts for financial year 2026 by 31-01-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.